<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article31</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/ACTIVE_A" style="display:block; margin-bottom:10px;">ACTIVE A Original</a></li>
<h2><strong>ACTIVE A</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>
<br/>
The New England Journal of Medicine. 2009. 360:2066-2078.<br/>
PubMed•Full text•PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
6.1 Inclusion Criteria<br/>
6.2 Exclusion Criteria<br/>
6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
8.1 Primary Outcome<br/>
8.2 Secondary Outcomes<br/>
9 Criticisms<br/>
10 Funding<br/>
11 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Among patients with atrial fibrillation at increased stroke risk that are unsuitable for vitamin K antagonist therapy, does the addition of clopidogrel to aspirin reduce the risk of vascular events?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In patients with atrial fibrillation unsuitable for vitamin K antagonist therapy and at increased risk for stroke, adding clopidogrel to aspirin reduced the risk of major vascular events, particularly stroke, but increased the risk of major hemorrhage.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
No specific guidelines were cited by the trial, but it was noted that VKAs are typically recommended for patients at a higher risk of stroke and aspirin for those at lower risk.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, double-blind, randomized, placebo-controlled trial<br/>
- N=7,554<br/>
- Clopidogrel (n=3,772) vs placebo (n=3,782), plus aspirin for all patients<br/>
- Median follow-up: 3.6 years<br/>
- Analysis: Intention-to-treat<br/>
- Primary outcome: Composite of stroke, myocardial infarction, non-CNS systemic embolism, or death from vascular causes<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria:<br/>
- Atrial fibrillation at enrollment or had at least two episodes in the previous 6 months<br/>
- At least one risk factor for stroke (age ≥75, hypertension, previous stroke/TIA/systemic embolism, left ventricular ejection fraction &lt;45%, peripheral artery disease, or age 55-74 plus diabetes or CAD)<br/>
<br/>
Exclusion Criteria:<br/>
- Required VKA or antiplatelet therapy, documented peptic ulcer disease within 6 months, history of intracerebral hemorrhage, significant thrombocytopenia, ongoing alcohol abuse<br/>
<br/>
Baseline Characteristics<br/>
- Mean age: 71 years<br/>
- 58.2% male<br/>
- Atrial fibrillation status: 63.7% permanent, 22.1% paroxysmal, 14.0% persistent<br/>
- Mean CHADS2 score: 2.0<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Patients were randomly assigned to receive either 75 mg/day of clopidogrel or matching placebo, in addition to recommended aspirin dose (75-100 mg/day)<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcome<br/>
- Primary composite outcome occurred in 832 patients receiving clopidogrel (6.8% per year) vs 924 patients receiving placebo (7.6% per year) [RR 0.89; 95% CI 0.81-0.98; P=0.01]<br/>
<br/>
Secondary Outcomes<br/>
- Stroke: 296 patients with clopidogrel (2.4% per year) vs 408 placebo (3.3% per year) [RR 0.72; 95% CI 0.62-0.83; P&lt;0.001]<br/>
- Myocardial infarction: 90 patients with clopidogrel (0.7% per year) vs 115 placebo (0.9% per year) [RR 0.78; 95% CI 0.59-1.03; P=0.08]<br/>
- Major bleeding: 251 patients with clopidogrel (2.0% per year) vs 162 placebo (1.3% per year) [RR 1.57; 95% CI 1.29-1.92; P&lt;0.001]<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/><br/>
- The trial has limited applicability to patients who are not at such a high risk of bleeding or who are capable of taking VKAs.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
- Funded by grants from Sanofi-Aventis and Bristol-Myers Squibb<br/>
- Authors disclosed various personal fees from these and other pharmaceutical companies<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/><p></p>
</div>
</div>
</div>
</div>
</body>
</html>
